Odyssey Therapeutics

Executive Summary

Odyssey Therapeutics is a private biotechnology company headquartered in Boston, focused on discovering and developing novel therapeutics for oncology and immunology. Founded in 2021, the company has raised $482 million to advance its integrated platform that combines biologics, small molecules, and computational tools to target complex disease pathways. Odyssey aims to create transformative medicines for patients with limited treatment options, leveraging its multi-modality approach to address challenging targets. The company is currently in Phase 1 clinical development, with several programs in early-stage clinical trials. Its pipeline includes candidates for both oncology and immunology indications, though specific details remain undisclosed due to competitive considerations. Given its substantial funding and innovative platform, Odyssey Therapeutics is positioned to generate significant clinical data over the next 12-18 months. The company's near-term value hinges on the successful execution of its ongoing Phase 1 trials and potential advancement of its pipeline into later-stage development. Key upcoming catalysts include initial clinical data readouts from its lead oncology program and regulatory milestones in immunology. However, as a private company, its development trajectory may be less transparent than public peers, and its valuation will depend on clinical proof-of-concept. Overall, Odyssey represents a high-risk, high-reward opportunity in precision medicine.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 data readout from lead oncology program40% success
• Q4 2026IND filing for a novel immunology candidate60% success
• TBDStrategic partnership or licensing deal for a platform asset50% success